Back to Search Start Over

After long-running patent battle, Vertex pays $100M to license Editas' gene-editing tech.

Authors :
Masson, Gabrielle
Source :
FierceBiotech; 12/13/2023, pN.PAG-N.PAG, 1p
Publication Year :
2023

Abstract

After an FDA nod for its SCD gene therapy, Vertex is paying $100M upfront for rights to Editas' Cas9 tech amid a long-standing patent battle. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
GENE therapy
PATENTS

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
174199193

Tools

Authors Abstract Subjects Details